CMND — Clearmind Medicine Income Statement
0.000.00%
Last trade - 00:00- $5.18m
- -$0.69m
Annual income statement for Clearmind Medicine, fiscal year end - October 31st, USD millions except per share, conversion factor applied.
2020 October 31st | R2021 October 31st | R2022 October 31st | 2023 October 31st | 2024 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.173 | 2.93 | 6.25 | 6.3 | 5.74 |
| Operating Profit | -0.173 | -2.93 | -6.25 | -6.3 | -5.74 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.173 | -2.96 | -6.87 | -8.6 | -4.88 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.173 | -2.96 | -6.89 | -8.62 | -5.25 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.173 | -2.96 | -6.89 | -8.62 | -5.25 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.173 | -2.96 | -6.89 | -8.62 | -5.25 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -9.56 | -95.4 | -159 | -42.6 | -1.69 |